biota provides progress update on gsk litigation, page-4

Great news that they state that...

"The July 2005 estimate [between $308m and $430m] may vary in the future...as documents are received from GSK and more information emerges about pandemic stockpiling of antiviral drugs, including Relenza"

Looks like $308m is the absolute bottom line and it is probable that the claim could be significantly higher than $430m - especially if seen as a % of the total market over the next few years.

Peter Molloy stated in the BioForum that "Sales of influenza antivirals this year could reach US$1billion and next year US$2billion or more. At the same time, and amid concerns about viral resistance to Tamiflu, the world is rediscovering the value of Relenza"